Software Equity Group

MAY 8, 2024

2023 saw a myriad of factors impact SaaS M&A multiples, including economic developments, technological advancements, and a public market rebound. In any given year, however, some sectors of the SaaS universe are more prosperous than others, depending on industry trends, global economics, and other influences.

M&A 52

M&A Valuation Economics Business 52

Intrepid Banker Insights

MARCH 28, 2023

Intrepid Investment Bankers Warning Signs Your Business’s Liquidity Needs Attention Mixed signals dominate economic headlines as concerns persist about a recession beginning in 2023, if it has not already begun. At the same time, employment remains strong, with the unemployment rate hitting an all-time low.

Capital 52

Capital Advisory Banking Bank 52

The Deal

JULY 20, 2023

The Paul Singer-led activist fund reported a 13% economic exposure to NRG Energy Inc. The memorandum noted that at most seven activist investors held gross positions of greater than $300 million — one of the proposal’s disclosure thresholds — on any given day during a yearlong sample period between 2021 and 2022.

Funds 52

Funds Investors Shares Investment 52

Wall Street Mojo

FEBRUARY 9, 2024

When listed as publicly traded companies, they mostly become small-cap and micro-cap stocks trading on the exchange. Such firms enjoy high growth rates and play a vital economic role. In 2022, the company generated an annual revenue of $9 million. With such financial reports, Ryan’s company falls in the LMM segment.

Middle Market 52

Middle Market Bulge Bracket Private Equity Investment Banking 52

Cooley M&A

SEPTEMBER 16, 2022

In addition, currently public dual-class companies with transfer provisions that do not contain clear carve outs for the delivery of voting agreements in the M&A context should discuss with their advisers the possibility of adopting “clear day” amendments to their charters to include these carve outs. Vote-down termination fee (i.e.,

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 20, 2022

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. on transactions dominating the life sciences landscape into 2022. [4].

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

DECEMBER 20, 2024

Cencora, one of the largest publicly-traded pharmaceutical companies in the world, distributes pharmaceuticals, over-the-counter healthcare products and other healthcare supplies and equipment to healthcare providers. Strong overall economic activity and lower interest rates. Other groups have sold within the private equity space.

Private Equity 52

Private Equity Healthcare Equities Sale 52

Cooley M&A

JANUARY 22, 2025

This stands in stark contrast to 2023, when life sciences M&A outperformed the market with a 50% increase in deal value from 2022 compared to a 17% decline in overall M&A activity across all industries. Luckily, theres more to this years story.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64